Author:
El-Ghobashy Nadeen M.,El-Sayed Selwan M.,Shehata Ihsan A.,El-Ashmawy Mahmoud B.
Abstract
AbstractMany benzoxazole-based and similar scaffolds were reported to have wide-range of anticancer activities. In this study, four series of benzoxazole derivatives were designed by combining benzoxazole scaffold with different amines via a reversed phenyl amide linker to produce the compounds of series A, B and C. A fourth new hybrid of benzoxazole with 1,2,3 triazole ring (series D) was also designed. The designed compounds were synthesized and screened for their anti-breast cancer activity against MDA-MB-231 and MCF-7 cell lines using MTT assay. The most potent cytotoxic compounds; 11–14, 21, 22, 25–27 were further evaluated for their in vitro PARP-2 enzyme inhibition. Compounds 12 and 27 proved to be the most active PARP-2 inhibitors with IC50 values of 0.07 and 0.057 µM, respectively. Compounds 12 and 27 caused cell cycle arrest in mutant MCF-7 cell line at G2/M and G1/S phase, respectively and they possessed significant apoptosis-promoting activity. Docking results of compounds 12 and 27 into PARP-2 pocket demonstrated binding interactions comparable to those of olaparib. Their predicted pharmacokinetic parameters and oral bioavailability appeared to be appropriate. Collectively, it could be concluded that compounds 12 and 27 are promising anti-breast cancer agents that act as PARP-2 inhibitors with potent apoptotic activity.
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. https://www.who.int/news-room/fact-sheets/detail/breast-cancer. Accessed January 29, 2022.
2. http://ascopost.com/issues/march-25-2021/cancer-control-in-egypt. Accessed January 29, 2022.
3. Geenen, J., Linn, S. C., Beijnen, J. H. & Schellens, J. PARP Inhibitors in the treatment of triple-negative breast cancer. Clin. Pharmacokinet. 57, 427–437. https://doi.org/10.1007/s40262-017-0587-4 (2018).
4. Gurkan-Alp, A. S., Alp, M., Karabay, A. Z., Koc, A. & Buyukbingol, E. Synthesis of some benzimidazole-derived molecules and their effects on PARP-1 activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 breast cancer cell viability. Anticancer agents Med. Chem. 20, 1728–1738. https://doi.org/10.2174/1871520620666200502001953 (2020).
5. Zhou, Y., Tang, S., Chen, T. & Niu, M. M. Structure-based pharmacophore modeling, virtual screening, molecular docking and biological evaluation for identification of potential poly (ADP-Ribose) polymerase-1 (PARP-1) inhibitors. Mol. (Basel, Switzerland) 24, 4258. https://doi.org/10.3390/molecules24234258 (2019).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献